Results 191 to 200 of about 34,497 (254)

Spironolactone Treatment for Dermatologic Conditions is Associated With Blood Pressure Changes in Patients on Concomitant Antihypertensives: A Retrospective Cohort Study. [PDF]

Int J Dermatol
Chan R, Neubauer Z, Ong MM, Chernoff KA, Lipner SR.   +4 more
europepmc   +1 more source

Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors. [PDF]

Circ Res
Golec S, Vaidya A, Pitt B, Jaffe IZ.
europepmc   +1 more source

Finerenone vs. spironolactone to reduce adverse outcomes in patients with cardiac-kidney-metabolic syndrome complicated by atrial fibrillation: findings from the Tianjin atrial fibrillation project. [PDF]

Eur Heart J Open
Tian X, Liu X, Zhao J, Han X, Gu T, Chen KY, Korantzopoulos P, Lip GYH, Liu T.   +8 more
europepmc   +1 more source

Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art review. [PDF]

Heart Fail Rev
Van Spall HGC, Vardeny O.
europepmc   +1 more source

Cardiovascular events with esaxerenone versus spironolactone in hypertension. [PDF]

J Hum Hypertens
Nakayama T, Kaneko H, Suzuki Y, Okada A, Morita H, Fujiu K, Takeda N, Azegami T, Yokoo T, Takeda N, Node K, Yasunaga H, Hayashi K.   +12 more
europepmc   +1 more source

The impact of mineralocorticoid receptor antagonists on fat mass and fat metabolism. [PDF]

J Endocrinol Invest
Afsar B, Afsar RE, Maddukuri G.
europepmc   +1 more source

Mineralocorticoid Receptor Blockade Mitigates Loop Diuretic-Exacerbated Plasma Volume Contraction and Target-Organ Fibrosis in Angiotensin II-Induced Hypertension. [PDF]

Int J Mol Sci
Liu J, Zhang YH.
europepmc   +1 more source